ClinicalTrials.gg
RecruitingNCT05127720ACaSAUpdated Feb 24, 2026

Pacemaker-based Long-term Monitoring of Sleep Apnea

An observational study in Bradycardia, sponsored by Medical University Innsbruck. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Medical University Innsbruck · Observational

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Bradycardia with a site in Austria — 7 open to participants now, 7 under way, none of them phase 3. Bradycardia · Austria.

Planned enrollment
4th of 11
1,000 · median 870
Started
2021
the only one that year
Observational
11 of 26
5 open now
Registered
19th of 26
by date
Lead sponsor
1 of 26
Medical University Innsbruck

Among the 26 studies in Bradycardia with a site in Austria, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2021, is one of 11 observational ones, and was the 19th registered.

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

Browse Bradycardia studies →

Open to participants now

7 of the 26 studies in Bradycardia with a site in Austria are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 51 Bradycardia studies recruiting now, 34 (67%) set no upper age limit and 9 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Bradycardia with a site in Austria, or all of them as a file.
02

Study summary

This is a prospective, non-interventional cohort study. It tests the hypothesis that

  • Pacemaker-derived monitoring of sleep-related breathing disorders and/or daily physical activity predicts clinical outcome.
  • Autonomic imbalance defined by an increased periodic repolarisation dynamics (PRD) predicts clinical outcome in pacemaker patients.
  • Autonomic imbalance defined by an increased periodic repolarisation dynamics (PRD) predicts the occurrence of device-detected atrial fibrillation and/or device-detected sleep apnea.
  • Enviromental factors such as ambient temperature, humidity, precipitation, air pressure impacts device-detected atrial fibrillation and/or device-detected sleep apnea.
  • Variation of night-to-night device-detected sleep apnea shows sex-specific patterns and impacts device-detected atrial fibrillation burden, ventricular pacing rate in sick sinus syndrome and clinical outcomes.
  • Burden / variation of device-detected sleep apnea and/or device-detected atrial fibrillation correlates with the incidence and severity of common ophthalmologic diseases.
Read the detailed description

All forms of arrhythmias, sleep apnea during sleeping hours and physical activity using sensors in modern implanted pacemakers as well as autonomic imbalance measures will be correlated with the incidence and progression (within 5 years of follow-up) of common co-morbidities such as arterial hypertension, coronary artery disease, heart failure, COPD, peripheral artery disease, iron insufficiency. In a long follow up perspective major adverse cardiovascular events will be recorded and new risk scores will be developed, incorporating machine learning techniques.

03

Conditions studied

  • Bradycardia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with pacemakers are usually above the age of 65 years, and suffer from common co-morbidities such as arterial hypertension, coronary artery disease, heart failure, COPD, peripheral artery disease, iron insufficiency, sleep disordered breathing, obesity and/or physical inactivity / de-conditioning.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • implanted Microport TEO SR/DR or BOREA SR/DR or ALIZEA SR/DR pacemaker device
  • signed

Exclusion criteria

Exclusion Criteria:

  • any to perform a cardiac CT examination
  • \< 30 ml/min/1.73 m2
  • allergy against CT contrast medium
  • hyperthyreoism
  • inability of the patient to understand the study purpose and plan
  • inability of the patient to perform baseline examinations
  • pregnancy or breast-feeding; women with
  • estimated below one year
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes

Groups and cohorts

  • patients with severe sleep apnea

    defined by a pacemaker-derived mean RDI ≥ 20/h in the first 12 months after enrollment

  • patients with autonomic imbalance

    defined by PRD ≥ 5.75deg2 (native) and/or ≥ 3 deg2 (paced) assessed within the first 12 months of enrollment

  • patients with a sedentary lifestyle

    defined by a pacemaker-derived mean daily physical activity level \< 2h in the first 12 months after enrollment

06

What researchers measure

Primary outcomes

  1. 3P-MACE

    death, myocardial infarction and/or stroke

    Time frame: time to first event, follow up for 120 months

  2. device-detected atrial fibrillation

    first episode lasting more than 6 minutes or 24 hours

    Time frame: time to first event, follow up for 120 months

  3. device-detected atrial fibrillation

    total burden

    Time frame: after 1, 3, 5 years

  4. device-detected sleep apnea

    severity (RDI \< versus \> 20/h)

    Time frame: after 1, 3, 5 years

  5. device-detected sleep apnea

    variation

    Time frame: after 1, 3, 5 years

Secondary outcomes

  1. incidence of common opthalmological disease

    in correlation to device-detected sleep apnea and device-detected atrial fibrillation

    Time frame: assessed within the first year after study enrollment

  2. Deterioration of lung function

    conventional lung function testing

    Time frame: after 5 years

  3. Progression of subclinical peripheral artery disease

    sonography

    Time frame: after 5 years

  4. Progression of subclinical peripheral artery disease

    ABI

    Time frame: after 5 years

  5. QoL assessment

    EQ-5D-5L

    Time frame: after 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010 Jul 27;122(4):352-60. doi: 10.1161/CIRCULATIONAHA.109.901801. Epub 2010 Jul 12. PubMed 20625114 ↗
  • Luyster FS, Kip KE, Aiyer AN, Reis SE, Strollo PJ Jr. Relation of obstructive sleep apnea to coronary artery calcium in non-obese versus obese men and women aged 45-75 years. Am J Cardiol. 2014 Dec 1;114(11):1690-4. doi: 10.1016/j.amjcard.2014.08.040. Epub 2014 Sep 16. PubMed 25307200 ↗
  • Hla KM, Young T, Hagen EW, Stein JH, Finn LA, Nieto FJ, Peppard PE. Coronary heart disease incidence in sleep disordered breathing: the Wisconsin Sleep Cohort Study. Sleep. 2015 May 1;38(5):677-84. doi: 10.5665/sleep.4654. PubMed 25515104 ↗
  • Defaye P, de la Cruz I, Marti-Almor J, Villuendas R, Bru P, Senechal J, Tamisier R, Pepin JL. A pacemaker transthoracic impedance sensor with an advanced algorithm to identify severe sleep apnea: the DREAM European study. Heart Rhythm. 2014 May;11(5):842-8. doi: 10.1016/j.hrthm.2014.02.011. Epub 2014 Feb 19. PubMed 24561163 ↗
  • Marti-Almor J, Marques P, Jesel L, Garcia R, Di Girolamo E, Locati F, Defaye P, Venables P, Dompnier A, Barcelo A, Nagele H, Burri H. Incidence of sleep apnea and association with atrial fibrillation in an unselected pacemaker population: Results of the observational RESPIRE study. Heart Rhythm. 2020 Feb;17(2):195-202. doi: 10.1016/j.hrthm.2019.09.001. Epub 2019 Sep 4. PubMed 31493591 ↗
  • Moubarak G, Bouzeman A, de Geyer d'Orth T, Bouleti C, Beuzelin C, Cazeau S. Variability in obstructive sleep apnea: Analysis of pacemaker-detected respiratory disturbances. Heart Rhythm. 2017 Mar;14(3):359-364. doi: 10.1016/j.hrthm.2016.11.033. Epub 2016 Nov 23. PubMed 27890735 ↗
  • Mazza A, Bendini MG, Leggio M, De Cristofaro R, Valsecchi S, Boriani G. Continuous monitoring of sleep-disordered breathing with pacemakers: Indexes for risk stratification of atrial fibrillation and risk of stroke. Clin Cardiol. 2020 Dec;43(12):1609-1615. doi: 10.1002/clc.23489. Epub 2020 Nov 12. PubMed 33179808 ↗
  • Linz D, Brooks AG, Elliott AD, Nalliah CJ, Hendriks JML, Middeldorp ME, Gallagher C, Mahajan R, Kalman JM, McEvoy RD, Lau DH, Sanders P. Variability of Sleep Apnea Severity and Risk of Atrial Fibrillation: The VARIOSA-AF Study. JACC Clin Electrophysiol. 2019 Jun;5(6):692-701. doi: 10.1016/j.jacep.2019.03.005. Epub 2019 May 1. PubMed 31221356 ↗
  • Mazza A, Bendini MG, De Cristofaro R, Lovecchio M, Valsecchi S, Boriani G. Pacemaker-detected severe sleep apnea predicts new-onset atrial fibrillation. Europace. 2017 Dec 1;19(12):1937-1943. doi: 10.1093/europace/euw371. PubMed 28073884 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2041, 241 months after the start.

Of 73 observational studies under Bradycardia, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 96. This study's planned 241 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2021
First posted
Nov 19, 2021
StartActual
Nov 30, 2021
Primary completionEst.
Dec 31, 2041
CompletionEst.
Dec 31, 2041
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05127720
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Nov 30, 2021
Primary completion
Dec 31, 2041 (estimated)
Completion
Dec 31, 2041 (estimated)
Last update
Feb 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion